Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Moderna says its mRNA Access program could help with the next pandemic

By Brian Buntz | March 17, 2022

mRNA Access

Image courtesy of Moderna

Moderna’s mRNA Access program (Nasdaq: MRNA) enables researchers to use its mRNA technology platform for research projects related to emerging and neglected infectious diseases.

“It takes a community of scientists and disease experts to develop novel vaccines to tackle our greatest public health threats,” said Hamilton Bennett, Moderna’s senior director, vaccine access and partnerships.

“mRNA Access was born of the idea that we are stewards of our platform, and by allowing researchers to access that platform and leverage the preclinical, clinical, regulatory and manufacturing capabilities that we’ve created, we could accelerate the development of novel vaccines,” Bennett said.

To prepare for future pandemics, the company is keeping tabs on known and emerging pathogens that pose a considerable risk with the potential for devastating impact on lives around the globe.

Before the pandemic, Moderna had mRNA development candidates for various indications, including infectious diseases such as Cytomegalovirus (CMV) and Zika.

It was Spikevax, the company’s COVID-19 vaccine, that showed that its mRNA platform could enable the rapid development of safe and efficacious vaccines.

Moderna hopes that mRNA Access will complement its development efforts and attract talented scientists and disease experts who can translate their understanding of the immune markers of protection into effective mRNA-based vaccines.

“Moderna is interested in collaborating with scientists who have novel approaches to inducing these protective responses, as well as those that see an opportunity to improve on an existing approach by using mRNA,” a Moderna spokesperson said.

The company’s global public health portfolio aims to address known infectious diseases of significant impact. Moderna is also working on preparing for the next emerging threat, which the company calls ‘Disease X.'”

While the company’s current clinical portfolio includes vaccines targeting COVID-19, HIV, Nipah and Zika, Moderna will focus on other pathogens such as tuberculosis, malaria and dengue by 2025.

“Some of the priority pathogens have epidemic potential like Ebola, Nipah and MERS, but they are also prototypes for related pathogens,” a Moderna spokesperson said. “The prototype vaccine approach learns from vaccines developed against representative viruses to rapidly adapt to tackle other related pathogens, in this way, preparing for Disease X. The value of this prototype vaccine approach was demonstrated when early research on SARS-CoV-1 and MERS enabled Moderna’s rapid response to SARS-CoV-2.”


Filed Under: Drug Discovery, Infectious Disease
Tagged With: coronavirus, covid-19, Ebola, HIV, infectious diseases, MERS, Moderna, mRNA Access, Nipah, Zika
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

CureVac
CureVac files lawsuit against BioNTech over patent infringement 
Bavarian Nordic
U.S. purchases more monkeypox vaccine doses from Bavarian Nordic
covid-19 vaccine
FDA backs COVID-19 boosters with BA.4/5 spike proteins for fall
Pfizer-BioNTech
Pfizer and BioNTech forge new COVID-19 vaccine deal with U.S. government

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50